Athenex's intravenous paclitaxel
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:atccode |
L01 CD01
|
| gptkbp:casnumber |
33069-62-4
|
| gptkbp:clinical_trial |
ongoing
Phase 3 ongoing studies completed studies |
| gptkbp:clinical_use |
combination therapy
monotherapy |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to paclitaxel |
| gptkbp:dosage_form |
once every 3 weeks
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP2 C8 inhibitors |
| gptkbp:effective_date |
FDA approved
|
| gptkbp:excretion |
biliary excretion
|
| gptkbp:financial_support |
gptkb:educational_resources
patient assistance programs |
| gptkbp:formulation |
solution for infusion
|
| gptkbp:funding |
funded by government grants
funded by private investors |
| https://www.w3.org/2000/01/rdf-schema#label |
Athenex's intravenous paclitaxel
|
| gptkbp:indication |
gptkb:Oncology
ovarian cancer |
| gptkbp:ingredients |
gptkb:paclitaxel
|
| gptkbp:lifespan |
approximately 13 hours
|
| gptkbp:manufacturer |
gptkb:Athenex,_Inc.
|
| gptkbp:market_position |
available in the US
available in Europe |
| gptkbp:marketed_as |
Onyvide
|
| gptkbp:mechanism_of_action |
microtubule inhibitor
|
| gptkbp:packaging |
vial
|
| gptkbp:patient_population |
pediatric patients
adult patients |
| gptkbp:pharmacokinetics |
highly protein-bound
|
| gptkbp:provides_guidance_on |
ASCO guidelines
NCCN guidelines |
| gptkbp:research_focus |
biomarker studies
combination with immunotherapy |
| gptkbp:route_of_administration |
intravenous
IV infusion |
| gptkbp:safety_measures |
adverse event reporting
post-marketing surveillance |
| gptkbp:side_effect |
fatigue
nausea vomiting hair loss neutropenia |
| gptkbp:storage |
store at room temperature
|
| gptkbp:structure |
C47 H51 NO14
|
| gptkbp:supply_chain |
direct to hospitals
distributed by wholesalers |
| gptkbp:used_for |
treating cancer
|
| gptkbp:bfsParent |
gptkb:Athenex
|
| gptkbp:bfsLayer |
6
|